We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ondine Biomedical Inc. | LSE:OBI | London | Ordinary Share | CA68234M2058 | COM SHS NPV (CDI) |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 8.50 | 12,178 | 08:00:08 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 8.00 | 9.00 | 9.00 | 8.50 | 8.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | CAD 1.2M | CAD -14.41M | CAD -0.0357 | -2.38 | 34.34M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 14:52:17 | O | 12,178 | 8.21 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 17/12/2024 | 07:00 | UK RNS | Ondine Biomedical Inc. Ondine commencing US Phase 3 clinical trial |
| 25/11/2024 | 17:00 | UK RNS | Ondine Biomedical Inc. Notification of Major Holdings |
| 22/11/2024 | 10:31 | UK RNS | Ondine Biomedical Inc. Notification of Major Holdings |
| 22/11/2024 | 08:30 | UK RNS | Ondine Biomedical Inc. Director Holdings |
| 18/11/2024 | 17:00 | UK RNS | Ondine Biomedical Inc. NOTIFICATION OF MAJOR HOLDINGS |
| 15/11/2024 | 15:30 | UK RNS | Ondine Biomedical Inc. Final Result of Fundraise & TVR |
| 14/11/2024 | 07:00 | UK RNS | Ondine Biomedical Inc. Updated Result of Fundraise |
| 11/11/2024 | 07:00 | UK RNS | Ondine Biomedical Inc. Update on Private Placement and Placing |
| 01/11/2024 | 15:34 | UK RNS | Ondine Biomedical Inc. Result of Fundraise |
| 01/11/2024 | 10:47 | ALNC |  Ondine Biomedical shares climb as raises funds for US clinical study |
Ondine Biomedical (OBI) Share Charts1 Year Ondine Biomedical Chart |
|
1 Month Ondine Biomedical Chart |
Intraday Ondine Biomedical Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 20/12/2024 | 21:13 | OBI | 131 |
| 19/12/2024 | 08:48 | Steriwave is on track to be approved in the US in 2024 | 523 |
| 07/11/2024 | 07:52 | O B I | 678 |
| 31/8/2023 | 11:28 | Potential | 8 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 21/12/2024 08:20 by Ondine Biomedical Daily Update Ondine Biomedical Inc. is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker OBI. The last closing price for Ondine Biomedical was 8.50p.Ondine Biomedical currently has 404,004,731 shares in issue. The market capitalisation of Ondine Biomedical is £34,340,402. Ondine Biomedical has a price to earnings ratio (PE ratio) of -2.38. This morning OBI shares opened at 8.50p |
Posted at 19/12/2024 22:20 by jailbird Yes purple will sell, we know he is a short term trader, but his 31k ain't gonna tank the share price |
Posted at 17/12/2024 07:22 by bamboo2 Ondine commencing US Phase 3 clinical trialOndine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces the imminent start of the LANTERN Phase 3 clinical trial of its novel nasal photodisinfection technology, branded as Steriwave® outside the US. The U.S. Food and Drug Administration (FDA) has raised no objections to starting the study during its statutory 30-day review period of the Company's Investigational New Drug (IND) amendment, thereby allowing the trial to begin. Preparations for this pivotal trial are nearly complete, with all 14 hospital sites selected and two additional back-up sites identified. Ondine has already initiated four sites and has been conducting staff training to ensure readiness for patient enrolment. Patient recruitment activities are beginning and will continue through early 2025, with the final patient expected to enrol in mid-2025. Early trial results are projected for release in Autumn 2025. The Phase 3 trial is being conducted in collaboration with HCA Healthcare, a leading healthcare provider in the United States. This group-randomized crossover study will enroll approximately 5,000 surgical patients undergoing cardiac, orthopedic, vascular, neuro or radical mastectomy surgeries. The study will compare standard infection prevention practices with and without Ondine's nasal photodisinfection technology. CEO Carolyn Cross stated: "The significant recent funding has been pivotal in enabling us to move forward with the launch of our US Phase 3 trial before the end of the year. This critical study marks a key milestone in our pursuit of FDA approval for our nasal photodisinfection technology. We're thrilled by the strong engagement from our clinical trial investigators and hospital research teams and are excited to commence the trial with the support of our clinical trial partner, HCA Healthcare." Ondine's nasal photodisinfection is a 5-minute, non-invasive procedure that rapidly decolonizes the nose of infection-causing pathogens without the use of antibiotics. This innovative approach avoids contributing to antimicrobial resistance (AMR). The process involves applying a proprietary photosensitive agent to each nostril with a nasal swab, followed by illumination with a specific wavelength of red light. The light activates the agent, producing an oxidative burst that destroys bacteria, viruses and fungi in a single treatment. Nasal decolonization is recommended in the 2016 WHO Global guidelines for the prevention of surgical site infections,[1] and the Society for Healthcare Epidemiology of America (SHEA) guidelines, published in May 2023, recommend nasal decolonization for major surgical procedures.[2] |
Posted at 14/11/2024 08:18 by bamboo2 Updated Result of FundraiseAll references to C$ in this announcement are to Canadian Dollars. This Announcement uses a C$:£ exchange rate of 1 : 0.5626 as at 16:30 (GMT) on 12 November 2024. Capitalized terms used in this announcement (this "Announcement") have the meanings given to them in the Proposed Fundraise announcement, unless the context provides otherwise. Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company, announces a further update to its Private Placement announced on 24 September 2024 and the Fundraising announced on 1 November 2024. The Company has no further clarity on the timing of the completion of the Private Placement but remains confident that this should complete in due course. Further updates will be provided when available. The Company announced on 1 November that certain of the directors of the Company have conditionally subscribed for, in aggregate, 2,479,035 Subscription Shares at the Issue Price. Since then, Carolyn Cross, CEO, has indicated her intention to subscribe for additional Subscription Shares and Nicolas Loebel, President and CTO, has indicated an intention to subscribe for Subscription Shares. In addition, the number of Subscription Shares to be issued to the relevant directors as set out in the 1 November announcement has been updated to take account of exchange rate variations. The Company can now confirm that Carolyn Cross, CEO, Robert Cross, husband to Carolyn Cross and Nicolas Loebel, President and CTO, intend to subscribe for a total of 19,372,003 Subscription Shares at the Issue Price (being 8.5 pence per Share). Furthermore, the Company has agreed with certain of its employees and vendors to settle payables in exchange for 1,816,670 shares in aggregate, also by way of subscription, thereby increasing the total number of Subscription Shares being subscribed for to 22,365,654 Subscription Shares. Therefore, the Subscription is now expected to raise gross proceeds of approximately C$3.6 million (c.£2.0 million). The Placing conditionally raised aggregate gross proceeds of approximately C$15.6 million (£8.8 million) pursuant to the placing of 103,403,318 Placing Shares with new and existing investors at the Issue Price. Therefore, the total gross proceeds from the Fundraising (being the Placing and the Subscription) is now expected to be c. C$19.2 million (c.£10.8 million), increased from c. C$16.2 million (£9.0 million announced on 1 November 2024. The estimated net proceeds are expected to be approximately C$18.1 million (c.£10.2 million), increased from c. C$15.1 million (c.£8.3 million). The Company confirms that admission and settlement of the 103,403,318 Placing Shares and 12,437,111 Subscription Shares amounting to c. C$17.7 million (c.£10.0 million) is now expected to take place on 18 November 2024 with the remaining 9,928,543 Subscription Shares amounting to C$1.5 million (c.£0.8 million), expected to be admitted to trading on AIM on or around 22 November 2024. The 125,768,972 New Common Shares, in aggregate to be issued pursuant to the Fundraising, represent approximately 45.2% per cent of the existing issued share capital of the Company. All shares issued pursuant to the Fundraising will be issued on a non pre-emptive basis under the Company's existing authorities. Increased Subscription & Related Party Transactions Certain of the directors of the Company intend to subscribe for, in aggregate, 20,548,984 Subscription Shares, to raise gross proceeds of approximately C$3.1 million (c.£1.75 million) for the Company, representing approximately 16.3 per cent of the New Common Shares from the completed Placing and the Subscription participations. Carolyn Cross and Robert Cross intend to subscribe for 18,710,100 New Common Shares. This is made up of: · A c.$0.9 million repayment of some of the outstanding balances due to Carolyn Cross, in exchange for 5,935,374 Subscription Shares. This is an increase of c.$0.7 million over the figure announced on 1 November 2024 ("Carolyn Cross' Enlarged Subscription"). · Conversion of C$130k (c. £73k) outstanding bonus due to Carolyn Cross into 860,474 Subscription Shares. · A subscription from Robert Cross amounting to 11,914,252 Subscription Shares for C$1.8 million (c.£1.0 million), to be paid in two tranches. The first tranche is for 1,985,709 Subscription Shares amounting to C$0.3 million (c.£0.17 million) ("Robert Cross' First Subscription"). The second tranche is for 9,928,543 Subscription Shares amounting to C$1.5 million (c.£0.84 million) ("Robert Cross' Second Subscription"). The number of New Common Shares, for which each of the Directors intend to subscribe, and their resulting shareholdings following the Admission of the Placing Shares and the Subscription Shares subscribed for to date, are set out below: Director Number of New Common Shares subscribed for in the Subscription Total Number of New Common Shares held on Admission % of issued share capital as enlarged by the completed Placing and Subscription2 Carolyn Cross1 18,710,100 155,864,029 38.58% Nicolas Loebel 661,903 3,513,991 0.87% Jean Duval 419,912 1,164,540 0.29% Junaid Bajwa 384,920 1,194,623 0.30% Margaret Shaw 197,186 214,328 0.05% Michael Farrar 174,963 485,228 0.12% 1 Existing beneficial holding includes 111,295,529 shares held by Carolyn Cross, including via holdings in 100% owned companies, and 25,858,400 shares held by Robert Cross, husband of Carolyn Cross. Following admission, the holdings will increase to 118,091,377 and 37,772,652 shares respectively. 2 Including issuance of 9,928,543 shares to Robert Cross to close on or about 22 November 2024. As previously announced, Carolyn Cross, CEO, provided loans, in aggregate, of C$1.245 million, to the Company (the "Loans") for additional working capital. Following the Subscription, the total outstanding loan balance is C$345,000, which may be repaid or converted to shares at 8.5 pence at a later date, subject to Board approval. The loan carries no interest and has no specific terms for repayment. The intended subscriptions by the Participating Directors will constitute related party transactions for the purposes of Rule 13 of the AIM Rules by virtue of such Persons being Directors of the Company. These Directors intend to participate at the same Issue Price as the Investors. Use of Proceeds and Further Funding The combined funds will be used to conduct the Company's US-based Phase 3 clinical trial for its Steriwave® nasal photodisinfection system, drive commercialization in approved markets, and support the Company's working capital needs, securing a cash runway into late Q2 2025. Together with the C$5 million (circa £2.8 million) Canadian Private Placement announced 24 September 2024, which will be settled in due course, the Company will have cash runway to early Q4 2025 and anticipated Phase 3 topline results In the event that the Company concludes the ongoing discussions with a major U.S. healthcare group regarding a potential investment of up to US$4 million (£3.1 million) the Company's expected cash runway would be into Q1 2027. Admission, Settlement and Dealings Admission of a total of 115,840,429 New Common Shares is expected to take place on or around 8.00 a.m. on 18 November 2024 with dealings on AIM in the commencing at the same time. Admission of the 9,928,543 shares under Robert Cross' Second Subscription is expected to take place on or around 8.00 a.m. on 22 November 2024 with dealings on AIM in the commencing at the same time. Admission is conditional upon, among other things, the Placing Agreement not having been terminated and becoming unconditional in all respects. The Placing Shares and Subscription Shares when issued, will be fully paid and will rank pari passu in all respects with the Existing Common Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue. |
Posted at 01/11/2024 18:04 by bamboo2 1 November 2024Ondine Biomedical Inc. ("OBI", "Ondine", or the "Company") Successful Fundraise, Upsized to C$16.2 million (£9.0m) Ondine secures funding for US Phase 3 clinical trial. Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company, is pleased to confirm, further to the announcement made earlier today (the "Launch Announcement"), the successful completion of the Placing and Subscription at the Issue Price of 8.5 pence per New Common Share. The Issue Price represents a premium of approximately 1.5 per cent. to the closing price of the Common Shares on 31 October 2024 of 8.375 pence. The total gross proceeds of the Fundraising have been upsized from the initial target of £8.5m, and are approximately C$16.2 million (£9.0 million) and the estimated net proceeds are expected to be approximately C$15.1 million (£8.3 million). The Placing has conditionally raised aggregate gross proceeds of approximately C$15.8 million (£8.8 million) pursuant to the placing of 103,403,318 Placing Shares with new and existing investors. The Subscription has raised further gross proceeds of approximately C$0.38 million (£0.21 million) pursuant to subscriptions received for 2,479,035 Subscription Shares. Carolyn Cross, CEO of Ondine, said: "With this key financing behind us, we are ready to embark on our key Phase 3 clinical trial in the USA and the first ICU trial in Canada. We are so grateful for the ongoing strong support of our shareholders, many representing top tier institutional investors and are very pleased to welcome significant new shareholders, including M&G Investment Management Limited, to the Company's share register." The 105,882,353 New Common Shares in aggregate to be issued pursuant to the Placing and the Subscription represent approximately 38 per cent. of the existing issued share capital of the Company. All shares issued pursuant to the Placing and Subscription will be issued non pre-emptively under the Company's existing authorities and are expected to be admitted to trading on AIM on or around 11 November 2024. RBC Europe Limited ("RBC"), Orana Corporate LLP ("Orana") and Oberon Capital, a trading name of Oberon Investments Limited, ("Oberon") acted as Joint Brokers to the Placing, and RBC and Oberon acted as Joint Bookrunners. The Placing was conducted following a market sounding by way of an accelerated bookbuild process. Related Party Transaction Certain of the directors of the Company have conditionally subscribed for, in aggregate, 2,479,035 Subscription Shares at the Issue Price, raising gross proceeds of approximately C$0.38 million (£0.21 million) for the Company, representing approximately 2.3 per cent of the New Common Shares from the completed Placing and the Subscription participations. The number of New Common Shares conditionally subscribed for by each of the Directors, and their resulting shareholdings following the Admission of the Placing Shares and the Subscription Shares subscribed for to date, are set out below: Director Number of New Common Shares subscribed for in the Subscription Total Number of New Common Shares held on Admission % of issued share capital as enlarged by the completed Placing and Subscription2 Carolyn Cross1 1,305,188 138,459,117 34.07% Jean Duval 420,923 1,164,540 0.29% Junaid Bajwa 385,846 1,194,623 0.29% Margaret Shaw 197,661 214,328 0.05% Michael Farrar 175,385 485,228 0.12% 1 Existing beneficial holding includes 111,295,529 shares held by Ms Carolyn Cross, including via holdings in 100% owned companies, and 25,858,400 shares held by Mr Robert Cross, husband of Ms Carolyn Cross. 2 Including issuance of 22,222,222 shares pursuant to capital raise announced on 24 September 2024, which will complete ahead of Admission As previously announced, Carolyn Cross, CEO, provided loans of, in aggregate, C$1.245 million, to the Company (the "Loans") for additional working capital. Ms Cross's participation in the Subscription is facilitated through C$0.2 million repayment in exchange for the 1,305,188 subscription shares shown above. Following the Subscription, the total outstanding loan balance is C$1.045 million, which may be repaid or converted to shares at 8.5 pence at a later date, subject to Board approval. The loan carries no interest and has no specific terms for repayment. The subscriptions by the Participating Directors constitute a related party transaction for the purposes of Rule 13 of the AIM Rules by virtue of such persons being directors of the Company and therefore related parties (the "Transaction"). The director independent of the Participating Directors, being Hon. Jean Charest, considers, having consulted with the Company's nominated adviser, that the terms of the participation by the Participating Directors, are fair and reasonable insofar as the Company's shareholders are concerned. Admission, Settlement and Dealings Admission of the Placing Shares and Subscription Shares is expected to take place on or before 8.00 a.m. on 11 November 2024 with dealings on AIM in the Placing Shares and the Subscription Shares commencing at the same time. Admission is conditional upon, among other things, the Placing Agreement not having been terminated and becoming unconditional in all respects. The Placing Shares and Subscription Shares when issued, will be fully paid and will rank pari passu in all respects with the Existing Common Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue. Total Voting Rights Following admission of the Placing Shares and Subscription Shares, in addition to admission of 22,222,222 shares in connection with the private placement announced on 24 September 2024, the Company's issued and fully paid share capital will consist of 406,340,334 Common Shares, all of which carry one voting right per share. The Company does not hold any Common Shares in treasury. Therefore, the total number of Common Shares and voting rights in the Company will be 406,340,334 after the admission of the Placing Shares and the Subscription Shares and the shares connected with the private placement announced on 24 September 2024. |
Posted at 01/11/2024 08:44 by bamboo2 1 November 2024Ondine Biomedical Inc. ("Ondine" or the "Company") Proposed Minimum £8.5 million (C$15.3m) Fundraise Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company, announces a proposed fundraising to raise not less than c.£8.5 million (C$15.3 million) from new and existing shareholders. The fundraising is being implemented by way of a proposed placing (the "Placing") and subscription (the "Subscription") (together, the "Fundraising"). The Fundraising involves the issuance of common shares without par value in the capital of the Company ("New Common Shares") at the price of 8.5 pence per New Common Share (the "Issue Price"). The majority of the Company's Directors (together the "Participating Directors") intend to participate in the Subscription for a total of c.£0.21 million (C$0.38 million) in gross proceeds forming part of the Fundraising, with such Subscription being conducted in accordance with applicable Canadian prospectus exemptions. The primary objective of the Fundraising is to provide the Company with sufficient capital to conduct the U.S. Phase 3 clinical study for its nasal photodisinfection system (branded as Steriwave® outside the U.S.). Finalized with regulatory input and in close collaboration with HCA Healthcare, Ondine's U.S. clinical trial partner, the circa 5,000-patient group-randomized crossover study is to be carried out at 14 HCA hospital sites and will compare standard-of-care infection prevention practices with and without nasal photodisinfection. The Company plans to recruit the first patient by the end of 2024, with the final patient expected mid-2025, and an early data readout anticipated in Autumn 2025. To support these goals, the Company seeks to raise a minimum of £8.5 million (C$15.3 million) from investors through the Fundraising. An additional C$5 million (c.£2.8 million) is anticipated from the equity raise via private placement which was announced to the market on 24 September 2024 and is due to settle by 8 November 2024 (the "Private Placement"). Combined, the Fundraising and Private Placement are projected to raise at least £11.3 million (C$20.4 million), providing sufficient funds to complete the Phase 3 trial through the final patient recruitment, drive commercialization in approved markets, and support the Company's working capital needs, securing a cash runway into early H2 2025. Additionally, the Company is engaged in discussions with a major U.S. healthcare group regarding a potential investment of up to US$4 million (£3.1 million). While the terms and structure of this investment are still under negotiation, the Company aims to finalize the arrangement by the end of 2024. If secured, this additional US$4 million investment would extend the cash runway to early Q2 2026, including anticipated Phase 3 topline results and NDA submission. If these negotiations do not yield an agreement, the Board will explore alternative funding options to extend the cash runway beyond early H2 2025. · The firm indications received in respect of Fundraising participations, as at the time of this announcement, are expected to result in a total new issuance of not less than 100,000,000 New Common Shares, representing approximately 36 per cent of the existing issued share capital of the Company. · The Issue Price represents a premium of approximately 1.5 per cent to the closing price on 31 October 2024 of 8.375 pence. · The final number and allocation of the Placing Shares will be determined by RBC Capital Markets, Orana Corporate LLP and Oberon Capital, a trading name of Oberon Investments Limited, in agreement with the Company and the result of the Placing will be announced as soon as practicable after the release of this announcement. · The planned issue of the New Common Shares pursuant to the Fundraising will take place on a non-pre-emptive basis. The Fundraising is not being underwritten. Intended Participation by Participating Directors in the Subscription Certain Directors of the Company have indicated their intention to subscribe for, in aggregate, 2,479,035 Subscription Shares at the Issue Price, raising gross proceeds of c.£0.21 million (C$0.38 million) for the Company. The participation in the Fundraising by the Participating Directors will be effected by entry into Subscription Agreements between the relevant Director and the Company. The participations in the Fundraising would, in aggregate, constitute a related party transaction under Rule 13 of the AIM Rules. Further disclosures will be made in a subsequent announcement in relation to these dealings. About the Placing and Subscription Pursuant to the Subscription, the Company will privately offer New Common Shares at the Issue Price ("Subscription Shares") to a limited number of entities and individuals both within and outside of the United Kingdom, under applicable regulatory exemptions as appropriate. The Placing, offering New Common Shares at the same Issue Price as the Subscription, is being undertaken by RBC Europe Limited ("RBC"), Orana Corporate LLP ("Orana") and Oberon Capital, a trading name of Oberon Investments Limited, ("Oberon") as Joint Brokers to the Placing, and RBC and Oberon as Joint Bookrunners, via an accelerated bookbuild process (the "Bookbuild"). The Bookbuild will be launched immediately following the release of this Announcement and is expected to close on 1 November 2024 (or such later time as may be agreed between the Joint Brokers, the Joint Bookrunners and the Company). The Placing is subject to the terms and conditions set out in Appendix I below. The Placing, which is conditional upon, inter alia, Admission becoming effective and the Placing Agreement (as defined below) becoming unconditional and not being terminated, and the Subscription are being carried out within the Company's existing statutory authority to issue shares on a non pre-emptive basis. The number of Placing Shares will be agreed by the Company in conjunction with the Joint Brokers and the Joint Bookrunners, and the result of the Placing will be confirmed by a further announcement released as soon as practicable thereafter. The timing of the closing of the Placing and the Result of Placing Announcement, final allocations and the total size of the Placing shall be determined at the absolute discretion of the Company, the Joint Brokers and the Joint Bookrunners. No aspect of the Fundraising is being underwritten. Expected Timetable of Principal Events 2024 Announcement of the Fundraising 1 November Announcement of result of the Fundraising 1 November Admission and commencement of dealings in the Placing Shares and Subscription Shares 11 November |
Posted at 28/10/2024 08:16 by bamboo2 RNS non. Ondine continues commercial growthOndine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that it has made significant progress with the commercial roll-out of its novel nasal decolonization technology, Steriwave®, in both Canada and the UK. Steriwave is a simple 5-minute procedure that reduces healthcare-associate In the UK, two of the largest NHS Trusts, King's College Hospital NHS Trust and Leeds Teaching Hospitals NHS Trust, are initiating Steriwave treatment prior to surgery. Recently Ondine announced that has partnered with Mölnlycke Health Care, a world-leading MedTech company that specializes in innovative solutions for wound care and surgical procedures, to bring Ondine's Steriwave® nasal decolonization technology to the United Kingdom, EU, and Middle East markets. In Canada, Steriwave is being used routinely in five (half) of the country's top 10 largest hospitals: Royal Alexandra (Alberta), The Ottawa Hospital - Civic Campus (Ontario), Vancouver General (BC), University of Alberta Hospital, and the Queen Elizabeth II Hospital (Nova Scotia).[1] In the last few months, five additional Canadian healthcare facilities have started using Steriwave to decolonize patients undergoing orthopedic surgery. These include University Hospital of Northern British Columbia, Royal Inland Hospital, Eagle Ridge Hospital, Okanagan Health Surgery Centre, and Hawkesbury General Hospital. Steriwave is also being used in all five of British Columbia's Health Authorities and benefitting from expanding regional adoption. For example, Royal Inland is the fourth hospital in Canada's British Columbia Interior Health Authority to adopt Steriwave alongside Kelowna General, Penticton Regional, and Kootenay Boundary. Eagle Ridge Hospital became the third hospital to embrace Steriwave in the Fraser Health Authority, following Burnaby Hospital, one of the largest hospitals outside the city of Vancouver and the Royal Columbian Hospital, which will be the first hospital to trial Steriwave to prevent infections in ICUs. The four major hospitals in the Vancouver Coastal Health Authority - the first to adopt nasal photodisinfection - have deployed Steriwave in their presurgical infection prevention protocols. Nicole Walby, Clinical Operations Manager at Interior Health Authority, commented: "Steriwave has been fully embraced by patients and staff alike, with patients and their families feeling reassured by the added protection. It's made a noticeable difference at our facility, bringing a sense of ease and comfort to an otherwise serious environment. Preventing surgical site infection through important tools such as Steriwave is a top priority for our clinicians in upholding and improving patient experiences." One in nine hospital patients in Canada gets an HAI resulting in approximately 12,000 deaths a year.[2] HAIs are also becoming harder to treat due to rising rates of AMR which are making some commonly used antibiotics ineffective.[3] This has meant that one in 19 deaths in Canada is now attributable to antibiotic-resistant infections.[4] The cost of AMR to the Canadian healthcare sector is also projected to increase from $1.4 billion to $7.6 billion per year by 2050.[5] Steriwave is a novel antimicrobial treatment that uses a proprietary light-activated agent to decolonize the nose and rapidly eliminate infection-causing pathogens. The agent is applied to each nostril using a nasal swab and then illuminated with a specific wavelength of red light. The light activates the photodynamic agent, causing an oxidative burst that destroys infection-causing bacteria, viruses and fungi in a single, 5-minute treatment. The process works so rapidly that pathogens do not have the opportunity to develop resistance, making it a viable alternative to antibiotics. |
Posted at 23/10/2024 06:33 by bamboo2 King's College Hospital to run Steriwave pilotOndine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, confirms that King's College Hospital (KCH) will be running a pilot of its Steriwave® light-activated antimicrobial technology. KCH, a globally recognized leader in healthcare innovation and one of London's largest teaching hospitals, will be using Steriwave as part of a quality improvement initiative pilot focused on preventing hospital-acquired infections (HAIs). The pilot at KCH is due to start later this year. Ondine's Steriwave technology is a groundbreaking antimicrobial treatment that uses a proprietary light-activated agent to rapidly eliminate infection-causing pathogens. The agent is applied to each nostril using a nasal swab and then illuminated with a red light laser. The light activates the photodynamic agent, causing an oxidative burst that destroys infection-causing bacteria, viruses and fungi in a single, 5-minute treatment. The process works so rapidly that pathogens do not have the opportunity to develop resistance, making it a viable alternative to antibiotics. In March 2024, Mid Yorkshire Teaching NHS Trust became the first UK institution to adopt Steriwave as standard of care for preventing surgical site infections in hip and knee surgery patients. Following its addition to the NHS Supply Chain in June 2024, Steriwave has become more accessible to hospitals and healthcare organizations across England and Wales, facilitating broader adoption of this innovative technology. |
Posted at 10/5/2024 06:12 by z1co 10/05/2024:ONDINE BIOMEDICAL INC. ("Ondine Biomedical", "Ondine", or the "Company") ECDC report shows HAIs are increasing antibiotic use A third of microorganisms causing HAIs (healthcare-associat Ondine Biomedical (LON: OBI): A recent report from the European Centre for Disease Prevention and Control (ECDC) helps underscore the need for Ondine's light-activated antimicrobial technology, a much-needed innovation in the face of growing antibiotic resistance. The report reveals an alarming increase in antibiotic use and rising resistance and finds that 4.3 million patients in EU/EEA hospitals are affected by healthcare-associate The report, "Point prevalence survey of healthcare-associate ECDC Director Dr. Andrea Ammon said: "Healthcare-associat With the threat of antibiotic-resistant HAIs increasing year-on-year, there is a growing need for effective antimicrobials which do not generate resistance. Antimicrobial resistance (AMR) is responsible for 1.27 million deaths a year and is one of humanity's most urgent global public health threats.[1] Ondine's Steriwave light-activated antimicrobial technology is highly effective against all types of pathogens-viruses, bacteria and fungi-including those that cause HAIs, even those resistant to antibiotics. Steriwave is a broad-spectrum light-activated antimicrobial that uses a patented photosensitizer and associated red light to destroy pathogens in the nose. The nose is a major reservoir of bacteria, fungi, and viruses, which can spread from there to cause serious infections. Unlike traditional antibiotics, Steriwave is immediately effective with a single five-minute treatment and does not trigger AMR. In 2023, Ondine presented research at the 2023 International Consortium on Prevention & Infection Control (ICPIC) in Geneva, demonstrating that Steriwave was highly effective (>99.99% kills in 20 seconds) against both moderately drug-resistant (MDR) and extensively drug-resistant (XDR) bacteria.[2] Ondine's Steriwave technology is already used in the UK in the NHS and extensively in hospitals across Canada to prevent HAIs. In 2024, hospitals in Spain became the first in the EU to adopt this groundbreaking technology. The prestigious Hospital Universitario La Paz (HULP), a large tertiary hospital in Madrid with 1,308 beds, is one of three Spanish hospitals using Steriwave. According to the latest ECDC HAI surveillance report, the prevalence rate of HAIs in Spain is 8.2% compared to the median of 6.8%. Spain also had higher rates of antibiotic usage, with over 45% of patients with an HAI receiving antibiotics. More than 150,000 patients have been treated with Steriwave to date, and no serious side effects have been reported. |
Posted at 11/1/2024 15:00 by z1co Since you like replying when you're called a troll.A special educational post for you troll. I've bought these shares for the 12 to 18 months time frame just like i bought CSFS over a year ago when they were around 6p to 7p. Take a look at CSFS price is up 5 fold. OBI share price will no doubt rise over the short , medium and long term. For your education you just keep watching and posting on the forum. nb I have available funds to buy more if i decide to. |
Posted at 05/12/2023 11:52 by bamboo2 5 December 2023Ondine Biomedical Inc. ("OBI", "Ondine", or the "Company") Result of Placing and Subscription Broker Option to raise up to GBP1.25 million Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company, is pleased to confirm, further to the announcement made on 30 November 2023, (the "Launch Announcement"), the successful completion of the Placing and Subscription at the Issue Price of 9 pence per New Common Share. The Issue Price represents a premium of approximately 9 per cent. to the closing mid-price of the Common Shares on 29 November 2023. The total gross proceeds of the Placing and the Subscription to date stand at approximately GBP2.75 million (C$4.74 million). The Placing has conditionally raised aggregate gross proceeds of approximately GBP2.03 million (C$3.50 million) pursuant to the placing of 22,554,435 Placing Shares with new and existing investors. The Subscription has raised further gross proceeds of approximately GBP0.72 million (C$1.24 million) pursuant to subscriptions received for 8,001,118 Subscription Shares, excluding any further subscriptions by employees (the "Employee Subscription"). The 30,555,553 New Common Shares in aggregate to be issued pursuant to the Placing and the Subscription represent approximately 15.7 per cent. of the existing issued share capital of the Company. All shares issued pursuant to the Placing and Subscription will be issued non pre-emptively under the Company's existing authorities, and are expected to be admitted to trading on AIM on or around 8 December 2023. Singer Capital Markets Securities Limited ("SCM") and RBC Europe Limited ("RBC") acted as Joint Bookrunners for the Placing. The Placing was conducted following a market sounding by way of an accelerated book build process. Further to the announcement on 4 December 2023, a Broker Option to raise up to GBP1.25 million (C$2.15 million) will remain open until 4.45pm on 8 December 2023, in order to satisfy potential further demand from institutional investors and other Relevant Persons. If the Broker Option is exercised in whole or in part, further announcements will be made as appropriate. Any further issuance of New Common Shares following any exercise of the Broker Option will be made on a non pre-emptive basis. Similarly, any further issuance pursuant to the Employee Subscription will be confirmed by way of a further announcement on or before 8 December 2023 and will be made on a non pre-emptive basis. The Employee Subscription will remain open until further notice, but will close in any event by 4.45 p.m. on 8 December 2023. Related Party Transaction Certain of the directors of the Company have conditionally subscribed for, in aggregate, 2,187,588 Subscription Shares at the Issue Price, raising gross proceeds of approximately GBP0.20 million (C$0.34 million) for the Company, representing approximately 7.2 per cent of the New Common Shares (assuming a Fundraising of approximately GBP2.75 million (C$4.74 million) from the completed Placing and the Subscription participations confirmed to date). The number of New Common Shares conditionally subscribed for by each of the Directors, and their resulting shareholdings following the Admission of the Placing Shares and the Subscription Shares subscribed for to date, assuming no new issuance is made arising from the exercise of the Broker Option or any further subscriptions by employees, are set out below: Director Number of New Total Number % of issued share Common Shares of New Common capital as enlarged subscribed for Shares held on by the completed in the Subscription Admission Placing and Subscription to date(1) Carolyn Cross(2) 1,093,770 135,328,279 59.98% -------------------- Nicolas Loebel 218,754 2,852,088 1.26% -------------------- Craig Tooman 173,278 173,278 0.08% -------------------- Jean Duval 207,934 207,934 0.09% -------------------- Junaid Bajwa 190,610 317,735 0.14% -------------------- Michael Farrer 86,642 86,642 0.04% -------------------- Simon Sinclair 216,600 472,927 0.21% -------------------- 1 These figures are subject to change in the event of further new issuance under the Employee Subscription or as a result of the exercise of some or all of the Broker Option. 2 Existing beneficial holding includes 108,376109 shares held by Mrs Carolyn Cross, including via holdings in 100% owned companies, and 25,858,400 shares held by Mr Robert Cross, husband of Mrs Carolyn Cross. The subscriptions by the Participating Directors constitute a related party transaction for the purposes of Rule 13 of the AIM Rules by virtue of such persons being directors of the Company and therefore related parties (the "Transaction"). The director independent of the Participating Directors, being Hon. Jean Charest, considers, having consulted with the Company's nominated adviser, that the terms of the participation by the Participating Directors, are fair and reasonable insofar as the Company's shareholders are concerned. Admission, Settlement and Dealings Admission of the Placing Shares and Subscription Shares will take place on or before 8.00 a.m. on 8 December 2023 and dealings on AIM in the Placing Shares and the Subscription Shares (excluding any to be issued from the Employee Subscription) will commence at the same time. Admission is conditional upon, among other things, the Placing Agreement not having been terminated and becoming unconditional in all respects. The Placing Shares and Subscription Shares when issued, will be fully paid and will rank pari passu in all respects with the Existing Common Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue. Total Voting Rights Following admission of the Placing Shares and Subscription Shares (excluding any arising from the Broker Option or Employee Subscription), the Company's issued and fully paid share capital will consist of 225,617,679 Common Shares, all of which carry one voting right per share. The Company does not hold any Common Shares in treasury. Therefore, the total number of Common Shares and voting rights in the Company will be 225,617,679 after the admission of the Placing Shares and the Subscription Shares (excluding any from the Broker Option Employee Subscription) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
